Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Past Highlights
Results:
1 -5 of 5
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
11/5/2003
 
First Published:
12/1/2001
1.
Phase I/II Study of Monoclonal Antibody Anti-anb3 Integrin in Patients With Irinotecan-Refractory Advanced Colorectal Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Closed
18 and over
NCI, Pharmaceutical / Industry
MSKCC-01078
MEDIMMUNE-MI-CP068, NCI-G01-2032, NCT00027729
2.
MEDI-522 in the Treatment of Patients With Metastatic Androgen-Independent Prostate Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Completed
18 and over
Pharmaceutical / Industry
MI-CP098
NCT00072930
Last Modified:
8/18/2004
 
First Published:
3/24/2004
3.
Phase II Randomized Study of Monoclonal Antibody Anti-Alpha V Beta 3 Integrin (MEDI-522) With or Without Dacarbazine in Patients With Unresectable Metastatic Melanoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Completed
18 and over
NCI, Pharmaceutical / Industry
MSKCC-03130
MEDIMMUNE-MI-CP095
Last Modified:
5/16/2006
 
First Published:
11/1/2002
4.
Phase I Study of Monoclonal Antibody Anti-alpha V beta 3 Integrin (MEDI 522) in Patients With Refractory Advanced Solid Tumors or Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Completed
18 and over
NCI
WCCC-CO-01905
NCI-5497, NCT00049712, 5497
5.
Study of the Tumor Saturation and Biological Activity of MEDI-522 (Abergrin) in Patients With Advanced Malignant Melanoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Completed
18 and over
Pharmaceutical / Industry
MI-CP121
CRRI #0305014, UPCI 05-025, NCT00111696
Select All on One Page
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute